title: Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Tae Kon
authors.identifier: http://orcid.org/0000-0002-5182-3870
authors.initials: TK
authors.lastname: Kim
authors.affiliation: Department of Pathology, Yale School of Medicine, New Haven, USA.
authors.forename: Mina L
authors.initials: ML
authors.lastname: Xu
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Nikolai A
authors.initials: NA
authors.lastname: Podoltsev
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Prebet
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Barbarotta
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Kejal
authors.initials: K
authors.lastname: Amin
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Kasberg
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Kristen
authors.initials: K
authors.lastname: Roche
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Stahl
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
authors.forename: Steven D
authors.initials: SD
authors.lastname: Gore
authors.affiliation: Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA. amer.zeidan@yale.edu.
authors.forename: Amer M
authors.initials: AM
authors.lastname: Zeidan
mesh_terms: D000369:Aged, 80 and over; D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D001943:Breast Neoplasms; D002295:Carcinoma, Transitional Cell; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000473:pathology; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D016879:Salvage Therapy; D001749:Urinary Bladder Neoplasms; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; D003561:Cytarabine; C510808:blinatumomab; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate